BR112021022635A2 - Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 - Google Patents
Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2Info
- Publication number
- BR112021022635A2 BR112021022635A2 BR112021022635A BR112021022635A BR112021022635A2 BR 112021022635 A2 BR112021022635 A2 BR 112021022635A2 BR 112021022635 A BR112021022635 A BR 112021022635A BR 112021022635 A BR112021022635 A BR 112021022635A BR 112021022635 A2 BR112021022635 A2 BR 112021022635A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino
- methylpyrazin
- decan
- azaspiro
- chloropyridin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858837P | 2019-06-07 | 2019-06-07 | |
| PCT/US2020/036137 WO2020247643A1 (en) | 2019-06-07 | 2020-06-04 | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021022635A2 true BR112021022635A2 (pt) | 2022-01-04 |
Family
ID=71787182
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021022635A BR112021022635A2 (pt) | 2019-06-07 | 2020-06-04 | Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11220501B2 (https=) |
| EP (1) | EP3980128A1 (https=) |
| JP (2) | JP2022534788A (https=) |
| KR (1) | KR20220019017A (https=) |
| CN (2) | CN115141205A (https=) |
| AU (1) | AU2020288631A1 (https=) |
| BR (1) | BR112021022635A2 (https=) |
| CA (1) | CA3142430A1 (https=) |
| IL (1) | IL288568A (https=) |
| MA (1) | MA56113A (https=) |
| MX (1) | MX2021014855A (https=) |
| PH (1) | PH12021552902A1 (https=) |
| SG (1) | SG11202112461QA (https=) |
| TW (1) | TW202112785A (https=) |
| WO (1) | WO2020247643A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| EP3980128A1 (en) | 2019-06-07 | 2022-04-13 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| CA2606288A1 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| KR101906146B1 (ko) * | 2009-08-17 | 2018-10-10 | 메모리얼 슬로안-케터링 캔서 센터 | 열 충격 단백질 결합 화합물, 조성물, 및 이의 제조 방법 및 사용 방법 |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| JP6523303B2 (ja) * | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 |
| KR102598895B1 (ko) * | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| SG11202009793TA (en) | 2018-04-10 | 2020-10-29 | Revolution Medicines Inc | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
| EP3980128A1 (en) * | 2019-06-07 | 2022-04-13 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
-
2020
- 2020-06-04 EP EP20746488.4A patent/EP3980128A1/en active Pending
- 2020-06-04 CN CN202210564150.XA patent/CN115141205A/zh active Pending
- 2020-06-04 AU AU2020288631A patent/AU2020288631A1/en not_active Abandoned
- 2020-06-04 MX MX2021014855A patent/MX2021014855A/es unknown
- 2020-06-04 CA CA3142430A patent/CA3142430A1/en active Pending
- 2020-06-04 MA MA056113A patent/MA56113A/fr unknown
- 2020-06-04 JP JP2021571896A patent/JP2022534788A/ja active Pending
- 2020-06-04 BR BR112021022635A patent/BR112021022635A2/pt not_active IP Right Cessation
- 2020-06-04 CN CN202080054905.0A patent/CN114190090A/zh active Pending
- 2020-06-04 TW TW109118750A patent/TW202112785A/zh unknown
- 2020-06-04 SG SG11202112461QA patent/SG11202112461QA/en unknown
- 2020-06-04 WO PCT/US2020/036137 patent/WO2020247643A1/en not_active Ceased
- 2020-06-04 KR KR1020227000184A patent/KR20220019017A/ko not_active Ceased
- 2020-06-04 PH PH1/2021/552902A patent/PH12021552902A1/en unknown
-
2021
- 2021-02-26 US US17/187,504 patent/US11220501B2/en active Active
- 2021-11-29 US US17/537,113 patent/US12528807B2/en active Active
- 2021-12-01 IL IL288568A patent/IL288568A/en unknown
-
2025
- 2025-06-18 JP JP2025101917A patent/JP2025138706A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020247643A1 (en) | 2020-12-10 |
| JP2025138706A (ja) | 2025-09-25 |
| SG11202112461QA (en) | 2021-12-30 |
| AU2020288631A1 (en) | 2021-12-09 |
| CA3142430A1 (en) | 2020-12-10 |
| MX2021014855A (es) | 2022-01-18 |
| US12528807B2 (en) | 2026-01-20 |
| EP3980128A1 (en) | 2022-04-13 |
| MA56113A (fr) | 2022-04-13 |
| PH12021552902A1 (en) | 2022-04-04 |
| IL288568A (en) | 2022-02-01 |
| US11220501B2 (en) | 2022-01-11 |
| CN115141205A (zh) | 2022-10-04 |
| JP2022534788A (ja) | 2022-08-03 |
| US20220298159A1 (en) | 2022-09-22 |
| KR20220019017A (ko) | 2022-02-15 |
| TW202112785A (zh) | 2021-04-01 |
| US20210253574A1 (en) | 2021-08-19 |
| CN114190090A (zh) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022635A2 (pt) | Formas sólidas de {6-[(2-amino-3-cloropiridin-4-il)sulfanil] 3 [(3s,4s) 4 amino-3-metil-2-oxa-8-azaespiro[4.5]decan-8-il]-5 metilpirazin 2-il}metanol, um inibidor de shp2 | |
| BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
| CR20220251A (es) | Nuevos derivados de metilquinazolinona | |
| CR20220234A (es) | Degradadores de moléculas pequeñas de helios y procedimientos de uso | |
| BRPI0515218A (pt) | composto, composição farmacêutica, método para o tratamento de um mamìfero ou ser humano, método de uso do composto, novos intermediários, uso dos novos intermediários, processo para a preparação de um composto | |
| CA3057882A1 (en) | Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein | |
| WO2019139899A8 (en) | Benzamide compounds | |
| BR112012003578A8 (pt) | Composto, sal farmaceuticamente aceitável, sal de sulfato, composição farmacêutica, método para tratar uma infecção viral, e, uso de um composto ou sal | |
| BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
| HN2003000348A (es) | Compuestos de benzofurano, composiciones y metodos para tratamiento y profilaxis de infeccion virales de hepatitis c y enfermedades asociadas. | |
| CL2023001894A1 (es) | Análogos de rifamicina y conjugados de fármaco-anticuerpo de los mismos | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| AU2020231934A8 (en) | Compounds useful in HIV therapy | |
| EP4321519A3 (en) | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders | |
| WO2021079196A3 (en) | Mettl3 modulators | |
| WO2018209363A3 (en) | PROPIONIC ACID DERIVATIVES AND ASSOCIATED METHODS OF USE | |
| BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
| BR112021018578A2 (pt) | Compostos de heterociclil(fenil)metanol úteis no tratamento de hiperglicemia | |
| AU2018274378A1 (en) | Compound used as autophagy regulator, and preparation method therefor and uses thereof | |
| BR112018015629A2 (pt) | ?composto, composição, método para tratar um mamífero infectado com o vírus hiv, e, proteína mutante tripla? | |
| BR112021018587A2 (pt) | Compostos de heteroaril(heterociclil)metanol úteis no tratamento de hiperglicemia | |
| BR112015028235A2 (pt) | (ciano-dimetil-metil)-isoxazóis e -[1,3,4]tiadiazóis | |
| MX2021012248A (es) | Polimorfos de voruciclib y metodos de elaboracion y uso de los mismos. | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| WO2022104153A3 (en) | Compounds and methods for treating viral infections |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |